Despite growing international acceptance of medical cannabis and evidence of benefit for some patients, Norway’s access to cannabis-based medicines has become more restricted rather than expanded. Norwegian health authorities took a cautious approach, channeling most use into clinical studies instead of establishing clear national guidelines. Funding was shifted from public reimbursement to hospitals, meaning many now must pay privately for treatment, which has reduced patient access by around 30%. Advocates argue that this creates unfairness and calls for regulated, safe access in medical settings.
Norway: Restricted access keeps medical cannabis out of reach
